Clinical trial
A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy With Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) Plus VINO-CPO Maintenance in Patients With High Risk Rhabdomyosarcoma (HR-RMS)
NCT04994132 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy With Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) Plus VINO-CPO Maintenance in Patients With High Risk Rhabdomyosarcoma (HR-RMS)
- Lead sponsor
- Children's Oncology Group
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- September 14, 2021
- Completion date
- July 1, 2027
- Enrollment
- 113 (actual)
- Sites
- 250
Conditions
As the registry lists them; a condition with its own page is linked.
alveolar rhabdomyosarcoma, botryoid-type embryonal rhabdomyosarcoma, embryonal rhabdomyosarcoma, metastatic embryonal rhabdomyosarcoma, metastatic rhabdomyosarcoma, solid alveolar rhabdomyosarcoma, spindle cell rhabdomyosarcoma, spindle cell/sclerosing rhabdomyosarcoma